| scholarly article | Q13442814 |
| P50 | author | Barton Haynes | Q4865631 |
| Susan Buchbinder | Q7647625 | ||
| Youyi Fong | Q57564569 | ||
| David C. Montefiori | Q63302725 | ||
| Georgia D. Tomaras | Q63663866 | ||
| Scott M. Hammer | Q78214286 | ||
| Barney S. Graham | Q89108863 | ||
| Allan C deCamp | Q89301907 | ||
| Richard A Koup | Q97635775 | ||
| Mark J Mulligan | Q104932176 | ||
| Shelly T Karuna | Q114519526 | ||
| Vicki C Ashley | Q125314217 | ||
| Julie McElrath | Q22006776 | ||
| P2093 | author name string | Peter B Gilbert | |
| Xiaoying Shen | |||
| Robert T Bailer | |||
| Ian Frank | |||
| Guido Ferrari | |||
| Lindsay N Carpp | |||
| Marcella Sarzotti-Kelsoe | |||
| Richard M Novak | |||
| Chenchen Yu | |||
| Edwin DeJesus | |||
| Edith Swann | |||
| Spyros Kalams | |||
| Kelly E Seaton | |||
| Aaron Deal | |||
| Holly E Janes | |||
| Magda Sobieszczyk | |||
| Michael Keefer | |||
| Nicole A Frahm | |||
| Shannon P Grant | |||
| P2860 | cites work | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 |
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine | Q30578618 | ||
| Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates | Q33742529 | ||
| Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination | Q33977866 | ||
| Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial | Q34374835 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies | Q35728947 | ||
| Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials | Q35762443 | ||
| Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates | Q35914306 | ||
| Nomenclature for Immune Correlates of Protection After Vaccination | Q35948780 | ||
| Weighted likelihood, pseudo-likelihood and maximum likelihood methods for logistic regression analysis of two-stage data | Q36843309 | ||
| Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. | Q36895518 | ||
| Complex immune correlates of protection in HIV-1 vaccine efficacy trials | Q39108779 | ||
| Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial | Q40332276 | ||
| Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. | Q46633111 | ||
| A framework for assessing immunological correlates of protection in vaccine trials | Q48689937 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1280-1288 | |
| P577 | publication date | 2018-03-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial | |
| P478 | volume | 217 |
| Q89813851 | A regularized estimation approach for case-cohort periodic follow-up studies with an application to HIV vaccine trials |
| Q90555329 | Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk |
| Q92756081 | Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial |
| Q98196674 | Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature |
| Q54233000 | Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses |
| Q90479100 | T cell-based strategies for HIV-1 vaccines |
Search more.